Adapted problem adaptation therapy for depression in mild to moderate Alzheimer's disease dementia: A randomized controlled trial

被引:4
|
作者
Howard, Robert [1 ]
Cort, Elizabeth [1 ]
Rawlinson, Charlotte [1 ]
Wiegand, Martin [2 ]
Downey, Anne [2 ]
Lawrence, Vanessa [3 ]
Banerjee, Sube [4 ]
Bentham, Peter [5 ]
Fox, Chris [6 ]
Harwood, Rowan [7 ]
Hunter, Rachel [2 ]
Livingston, Gill [1 ]
Moniz-Cook, Esme [8 ]
Panca, Monica [2 ]
Raczek, Malgorzata [9 ]
Ivenso, Chineze [10 ]
Russell, Gregor [11 ]
Thomas, Alan [12 ]
Wilkinson, Philip [13 ]
Freemantle, Nicholas [14 ]
Gould, Rebecca [1 ]
机构
[1] UCL, Div Psychiat, London, England
[2] UCL, Priment Clin Trials Unit, London, England
[3] Kings Coll London, David Goldberg Ctr H1 01, London, England
[4] Univ Plymouth, Plymouth, Devon, England
[5] Birmingham & Solihull NHS Trust, Birmingham, England
[6] Univ East Anglia, Norwich, Norfolk, England
[7] Univ Nottingham, Queens Med Ctr, Nottingham, England
[8] Univ Hull, Kingston Upon Hull, England
[9] Brighton & Sussex Sch Med, Brighton, E Sussex, England
[10] Aneurin Bevan NHS Trust, St Cadocs Hosp, Newport, Wales
[11] Bradford Dist Care Fdn Trust, Bradford, England
[12] Univ Newcastle, Campus Ageing & Vital, Newcastle Upon Tyne, England
[13] Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford, England
[14] UCL, Comprehens Clin Trials Unit, London, England
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; clinical trial; depression; mood; problem adaptation therapy; psychological; psychotherapy; MINI-MENTAL-STATE; ANXIETY; PEOPLE; SCALE;
D O I
10.1002/alz.13766
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
INTRODUCTION: Trials of effectiveness of treatment options for depression in dementia are an important priority. METHODS: Randomized controlled trial to assess adapted Problem Adaptation Therapy (PATH) for depression in mild/moderate dementia caused by Alzheimer's disease. RESULTS: Three hundred thirty-six participants with mild or moderate dementia, >7 on Cornell Scale for Depression in Dementia (CSDD), randomized to adapted PATH or treatment as usual. Mean age 77.0 years, 39.0% males, mean Mini-Mental State Examination 21.6, mean CSDD 12.9. For primary outcome (CSDD at 6 months), no statistically significant benefit with adapted PATH on the CSDD (6 months: -0.58; 95% CI -1.71 to 0.54). The CSDD at 3 months showed a small benefit with adapted PATH (-1.38; 95% CI -2.54 to -0.21) as did the EQ-5D (-4.97; 95% CI -9.46 to -0.48). DISCUSSION: An eight-session course of adapted PATH plus two booster sessions administered within NHS dementia services was not effective treatment for depression in people with mild and moderate dementia. Future studies should examine the effect of more intensive and longer-term therapy.
引用
收藏
页码:2990 / 2999
页数:10
相关论文
共 50 条
  • [21] The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer’s disease
    Raj C Shah
    Patrick J Kamphuis
    Sue Leurgans
    Sophie H Swinkels
    Carl H Sadowsky
    Anke Bongers
    Stephen A Rappaport
    Joseph F Quinn
    Rico L Wieggers
    Philip Scheltens
    David A Bennett
    Alzheimer's Research & Therapy, 5
  • [22] Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial
    Scheltens, Philip
    Kamphuis, Patrick J. G. H.
    Verhey, Frans R. J.
    Rikker, Marcel G. M. Olde
    Wurtman, Richard J.
    Wilkinson, David
    Twisk, Jos W. R.
    Kurz, Alexander
    ALZHEIMERS & DEMENTIA, 2010, 6 (01) : 1 - 10
  • [23] The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease
    Shah, Raj C.
    Kamphuis, Patrick J.
    Leurgans, Sue
    Swinkels, Sophie H.
    Sadowsky, Carl H.
    Bongers, Anke
    Rappaport, Stephen A.
    Quinn, Joseph F.
    Wieggers, Rico L.
    Scheltens, Philip
    Bennett, David A.
    ALZHEIMERS RESEARCH & THERAPY, 2013, 5 (06):
  • [24] Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial
    Pakdaman, Hossein
    Harandi, Ali Amini
    Hatamian, Hamidreza
    Tabatabae, Mojgan
    Kasmaei, Hosein Delavar
    Ghassemi, Amirhossein
    Gharagozli, Koroush
    Ashrafi, Farzad
    Naeini, Pardis Emami
    Tavakolian, Mehrnaz
    Shahin, Darush
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2015, 5 (01): : 96 - 106
  • [25] Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial (vol 283, pg 1007, 2000)
    不详
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (20): : 2597 - 2597
  • [26] Neuropsychological outcome of cognitive training in mild to moderate dementia: A randomized controlled trial
    Kallio, Eeva-Liisa
    Hietanen, Marja
    Kautiainen, Hannu
    Pitkala, Kaisu H.
    NEUROPSYCHOLOGICAL REHABILITATION, 2021, 31 (06) : 935 - 953
  • [27] Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer's disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET)
    Lang, Frederick M.
    Mo, Yi
    Sabbagh, Marwan
    Solomon, Paul
    Boada, Merce
    Jones, Roy W.
    Frisoni, Giovanni B.
    Grimmer, Timo
    Dubois, Bruno
    Harnett, Mark
    Friedhoff, Sarah R.
    Coslett, Shari
    Cummings, Jeffrey L.
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2021, 7 (01)
  • [28] Bapineuzumab for mild to moderate Alzheimer’s disease: a meta-analysis of randomized controlled trials
    Abdelrahman Ibrahim Abushouk
    Ahmed Elmaraezy
    Amro Aglan
    Reham Salama
    Samar Fouda
    Rana Fouda
    Ammar M. AlSafadi
    BMC Neurology, 17
  • [29] Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials
    Abushouk, Abdelrahman Ibrahim
    Elmaraezy, Ahmed
    Aglan, Amro
    Salama, Reham
    Fouda, Samar
    Fouda, Rana
    AlSafadi, Ammar M.
    BMC NEUROLOGY, 2017, 17
  • [30] Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease
    Honig, Lawrence S.
    Vellas, Bruno
    Woodward, Michael
    Boada, Merce
    Bullock, Roger
    Borrie, Michael
    Hager, Klaus
    Andreasen, Niels
    Scarpini, Elio
    Liu-Seifert, Hong
    Case, Michael
    Dean, Robert A.
    Hake, Ann
    Sundell, Karen
    Hoffmann, Vicki Poole
    Carlson, Christopher
    Khanna, Rashna
    Mintun, Mark
    DeMattos, Ronald
    Selzler, Katherine J.
    Siemers, Eric
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (04): : 321 - 330